Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NASDAQ:DSGN NASDAQ:ELVN NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$37.71-0.7%$34.69$23.23▼$42.29$1.20B0.63411,273 shs364,170 shsDSGNDesign Therapeutics$6.13-7.7%$4.70$2.60▼$7.77$378.14M1.61186,366 shs107,527 shsELVNEnliven Therapeutics$19.22-2.5%$20.37$13.30▼$30.03$1.17B0.89419,351 shs369,670 shsXERSXeris Biopharma$7.81+1.7%$6.37$2.66▼$8.03$1.24B0.132.02 million shs1.19 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical-0.68%-4.75%+4.34%+27.40%+4.55%DSGNDesign Therapeutics-7.68%+2.85%+27.18%+56.78%+8.69%ELVNEnliven Therapeutics-2.54%-8.26%+6.13%-2.24%-17.40%XERSXeris Biopharma+1.69%-0.38%+8.47%+76.70%+188.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$37.71-0.7%$34.69$23.23▼$42.29$1.20B0.63411,273 shs364,170 shsDSGNDesign Therapeutics$6.13-7.7%$4.70$2.60▼$7.77$378.14M1.61186,366 shs107,527 shsELVNEnliven Therapeutics$19.22-2.5%$20.37$13.30▼$30.03$1.17B0.89419,351 shs369,670 shsXERSXeris Biopharma$7.81+1.7%$6.37$2.66▼$8.03$1.24B0.132.02 million shs1.19 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical-0.68%-4.75%+4.34%+27.40%+4.55%DSGNDesign Therapeutics-7.68%+2.85%+27.18%+56.78%+8.69%ELVNEnliven Therapeutics-2.54%-8.26%+6.13%-2.24%-17.40%XERSXeris Biopharma+1.69%-0.38%+8.47%+76.70%+188.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 3.00Buy$42.3312.26% UpsideDSGNDesign Therapeutics 0.00N/AN/AN/AELVNEnliven Therapeutics 3.00Buy$41.20114.36% UpsideXERSXeris Biopharma 2.83Moderate Buy$7.08-9.30% DownsideCurrent Analyst Ratings BreakdownLatest DSGN, XERS, COLL, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025XERSXeris BiopharmaLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $9.008/12/2025XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.008/11/2025COLLCollegium PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$44.007/2/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $48.006/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$37.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.88$12.24 per share3.08$7.10 per share5.31DSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/AELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/AXERSXeris Biopharma$203.07M6.21N/AN/A($0.20) per share-39.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$69.19M$1.0436.266.26N/A5.13%97.28%13.87%11/6/2025 (Estimated)DSGNDesign Therapeutics-$49.59M-$1.12N/AN/AN/AN/A-27.15%-26.07%11/6/2025 (Estimated)ELVNEnliven Therapeutics-$89.02M-$2.00N/AN/AN/AN/A-29.15%-27.88%11/12/2025 (Estimated)XERSXeris Biopharma-$54.84M-$0.21N/AN/AN/A-13.01%N/A-8.00%11/14/2025 (Estimated)Latest DSGN, XERS, COLL, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ELVNEnliven Therapeutics-$0.53-$0.49+$0.04-$0.49N/AN/A8/7/2025Q1 2025DSGNDesign Therapeutics-$0.32-$0.34-$0.02-$0.34N/AN/A8/7/2025Q2 2025XERSXeris Biopharma-$0.03-$0.01+$0.02-$0.01$64.58 million$67.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.271.181.10DSGNDesign TherapeuticsN/A25.1325.13ELVNEnliven TherapeuticsN/A32.5832.58XERSXeris BiopharmaN/A1.951.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/ADSGNDesign Therapeutics56.64%ELVNEnliven Therapeutics95.08%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%DSGNDesign Therapeutics23.50%ELVNEnliven Therapeutics25.90%XERSXeris Biopharma6.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21031.50 million30.71 millionOptionableDSGNDesign Therapeutics4056.95 million43.57 millionOptionableELVNEnliven Therapeutics5059.24 million43.89 millionOptionableXERSXeris Biopharma290161.48 million151.03 millionOptionableDSGN, XERS, COLL, and ELVN HeadlinesRecent News About These CompaniesWhat Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?September 9 at 1:01 PM | zacks.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Significant Decline in Short InterestSeptember 9 at 2:57 AM | americanbankingnews.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Short Interest Down 26.7% in AugustSeptember 9 at 2:53 AM | marketbeat.comParkman Healthcare Partners LLC Has $9.78 Million Stock Position in Xeris Biopharma Holdings, Inc. $XERSSeptember 8 at 7:45 AM | marketbeat.comXeris Biopharma (NASDAQ:XERS) Downgraded by Wall Street Zen to BuySeptember 8 at 2:23 AM | marketbeat.comCubist Systematic Strategies LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERSSeptember 7, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. $XERS Stock Holdings Raised by Graham Capital Management L.P.September 7, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Stock Rating Lowered by Wall Street ZenSeptember 7, 2025 | americanbankingnews.comBosun Asset Management LLC Acquires New Holdings in Xeris Biopharma Holdings, Inc. $XERSSeptember 6, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Reaches New 12-Month High - Time to Buy?September 5, 2025 | marketbeat.comXeris In Recorlev-Fuelled Growth: Why I Choose To BuySeptember 5, 2025 | seekingalpha.comPDT Partners LLC Buys New Shares in Xeris Biopharma Holdings, Inc. $XERSSeptember 5, 2025 | marketbeat.comIeq Capital LLC Boosts Holdings in Xeris Biopharma Holdings, Inc. $XERSSeptember 5, 2025 | marketbeat.comQuarry LP Makes New $388,000 Investment in Xeris Biopharma Holdings, Inc. $XERSSeptember 3, 2025 | marketbeat.comAlpine Global Management LLC Has $549,000 Stock Position in Xeris Biopharma Holdings, Inc. $XERSSeptember 2, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. $XERS Shares Purchased by Driehaus Capital Management LLCSeptember 2, 2025 | marketbeat.comWellington Management Group LLP Has $2.15 Million Stake in Xeris Biopharma Holdings, Inc. $XERSSeptember 2, 2025 | marketbeat.comRussell Investments Group Ltd. Buys 113,713 Shares of Xeris Biopharma Holdings, Inc. $XERSSeptember 1, 2025 | marketbeat.comJeffrey Sherman Sells 42,232 Shares of Xeris Biopharma (NASDAQ:XERS) StockAugust 30, 2025 | insidertrades.comQuantbot Technologies LP Purchases Shares of 54,107 Xeris Biopharma Holdings, Inc. $XERSAugust 30, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. $XERS Stake Increased by Invesco Ltd.August 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDSGN, XERS, COLL, and ELVN Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$37.71 -0.26 (-0.68%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$37.70 -0.01 (-0.01%) As of 09/10/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Design Therapeutics NASDAQ:DSGN$6.13 -0.51 (-7.68%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$6.13 0.00 (0.00%) As of 09/10/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Enliven Therapeutics NASDAQ:ELVN$19.22 -0.50 (-2.54%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$19.22 0.00 (-0.03%) As of 09/10/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Xeris Biopharma NASDAQ:XERS$7.81 +0.13 (+1.69%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$7.82 +0.01 (+0.13%) As of 09/10/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
